DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo.
Christopher R LucasPatrick D HalleyAmjad A ChowduryBonnie K HarringtonLarry BeaverRosa LapalombellaAmy J JohnsonErin K HertleinMitch A PhelpsJohn C ByrdCarlos E CastroPublished in: Small (Weinheim an der Bergstrasse, Germany) (2022)
DNA origami (DO) nanotechnology enables the construction of precise nanostructures capable of functionalization with small molecule drugs, nucleic acids, and proteins, suggesting a promising platform for biomedical applications. Despite the potential for drug and vaccine delivery, the impact of DO vehicles on immunogenicity in vivo is not well understood. Here, two DO vehicles, a flat triangle and a nanorod, at varying concentrations are evaluated in vitro and with a repeated dosing regimen administered at a high dose in vivo to study early and late immunogenicity. The studies show normal CD11b + myeloid cell populations preferentially internalize DO in vitro. DO structures distribute well systemically in vivo, elicit a modest pro-inflammatory immune response that diminishes over time and are nontoxic as shown by weight, histopathology, lack of cytokine storm, and a complete biochemistry panel at the day 10 end point. The results take critical steps to characterize the biological response to DO and suggest that DO vehicles represent a promising platform for drug delivery and vaccine development where immunogenicity should be a key consideration.
Keyphrases
- small molecule
- high dose
- immune response
- drug delivery
- circulating tumor
- high throughput
- single molecule
- cell free
- dendritic cells
- body mass index
- single cell
- low dose
- bone marrow
- physical activity
- cell therapy
- acute myeloid leukemia
- stem cells
- weight loss
- emergency department
- stem cell transplantation
- weight gain
- toll like receptor
- inflammatory response
- nucleic acid
- mesenchymal stem cells
- risk assessment
- mass spectrometry
- adverse drug
- human health